Mode
Text Size
Log in / Sign up
N/A N=139 Randomized Single-blind Treatment

Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients

Alcohol Dependence · Chronic Hepatitis C

Enrolled (actual)
139
Serious AEs
15.1%
Results posted
Nov 2014
Primary outcome: Primary: The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up. — 14.88; 21.41 Standard Alcohol drinks

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Motivational Enhancement Therapy (MET) (Behavioral); Health education (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
US Department of Veterans Affairs
Primary completion
Jun 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up.
14.88; 21.41
PRIMARY
Percent Days Abstinent From Alcohol at 6 Months
73.15; 59.49
SECONDARY
Heavy Drinking Days (Greater or Equal to 4 Drinks)
5.10; 7.38

Summary

The purpose of this study is to determine whether motivational enhancement therapy (MET) reduces alcohol use in a population of HCV-infected veterans who are currently drinking alcohol and have alcohol disorders. We hypothesize that veterans with HCV, an alcohol use disorder and continued excessive alcohol use who receive MET will have a greater reduction in the number of standard alcohol drinks per week and a greater percentage of days abstinent than veterans who receive health education control intervention.

Eligibility Criteria

Inclusion Criteria

  • Male or Female age 18 or older
  • Serum antibody and polymerase chain reaction positive for hepatitis C
  • Drinking greater than 7 drinks for each of the proceeding 2 weeks or one day heavy drinking day per week for 2 week (heavy drinking day:>4 drinks in one day)
  • Diagnosed with alcohol abuse or dependence

Exclusion Criteria

  • Diagnosis of cocaine, methamphetamine or opioid dependence within the past 6 months
  • Unable to attend clinic appointments
  • Any known pre-existing medical conditions that could interfere with participation in the protocol, such as: CNS trauma, known cognitive impairment, dementia, encephalopathy from liver disease, acute psychiatric instability, such as significant psychosis, mania, or elevated risk for suicide
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00596960). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search